


Sex Differences of Frailty in Dialysis Patients

Ting-Yun Lin, MD

Division of Nephrology, Taipei Tzu Chi Hospital

Prevalence of frailty in ESKD



Associations and outcomes with frailty in dialysis patients

Associations	Outcomes
Morbidities	Lower bone mass ¹⁷ Higher rate of fall and fracture ^{5,15,17} Anxiety and depression ^{10,18} Cognitive impairment ² Disease symptom ¹⁸ Disability and institutionalization ^{7,10}
Hospitalization	Higher rate of emergency room attendance ⁵ Shorter time to first hospitalization ¹⁴ Higher rate of hospitalization ^{4,5,7,11,19} Longer duration of hospitalization ^{4,19} Higher hospitalization expenditure ²⁰
Cardiovascular	Higher rate of cardiovascular event ^{19,21}
Infection	Higher rate of infection-related hospitalization ⁴
Transplant-related	Less likely to be waitlisted ⁴ Higher chance of being delisted ⁴ Higher rate of waitlist mortality ^{4,22} Higher rate of delayed graft function ²³ Longer duration of postoperative hospitalization ²³
Dialysis-specific	Slower rate of vascular access (arteriovenous fistula and graft) maturation ²⁴ Higher rate of vascular access thrombosis ^{12,25} More frequent vascular access revision and/or intervention ²⁴ Increased peritoneal dialysis-associated peritonitis rate ²
Survival	Higher rate of mortality ^{1,7,11}

Predictors of frailty among incident dialysis patients

The Comprehensive Dialysis Study (CDS)

- ✓ 1576 incident patients receiving hemodialysis
- ✓ A modified version of Fried's criteria—comprising slowness/weakness, exhaustion, and low physical activity—was applied.
- ✓ Frailty was defined as a score of two or higher.



Variable	Frail	
	OR (95% CI)	P Value
Age, per 10 y	1.00 (0.90-1.11)	.98
Male sex	0.49 (0.39-0.62)	<.001
White race	1.25 (0.96-1.62)	.10
Medicaid, vs other payers	1.70 (1.22-2.36)	.002
Current smoker	1.27 (0.76-2.13)	.36
eGFR, per 5 mL/min/1.73 m ² increase	1.44 (1.23-1.68)	<.001
Albumin quartiles/missing		.37 for trend
Group 1: ≤2.5 g/dL	0.98 (0.66-1.46)	.92
Group 2: >2.5-3.0 g/dL	1.12 (0.78-1.61)	.55
Group 3: missing	1.11 (0.80-1.54)	.53
Group 4: >3.0-3.5 g/dL	1 [Reference]	
Group 5: >3.5 g/dL	0.85 (0.61-1.20)	.35
Hemoglobin quartiles/missing		.07 for trend
Group 1: ≤9 g/dL	1 [Reference]	
Group 2: >9-10 g/dL	1.07 (0.76-1.51)	.69
Group 3: missing	0.99 (0.63-1.57)	.97
Group 4: >10-12 g/dL	1.04 (0.77-1.42)	.80
Group 5: >12 g/dL	1.61 (1.02-2.53)	.04
Hemodialysis	1.04 (0.71-1.53)	.84
Comorbidity		
Diabetes mellitus	1.52 (1.18-1.96)	.001
Congestive heart failure	1.27 (0.94-1.70)	.11
Atherosclerotic heart disease	0.96 (0.68-1.34)	.80
CVA/TIA	1.85 (1.04-3.28)	.04
Peripheral vascular disease	1.67 (1.16-2.41)	.006
COPD	1.77 (0.96-3.25)	.07
Cancer	1.19 (0.70-2.03)	.52

Factors associated with frailty

A prospective Taiwanese cohort study

- ✓ 761 prevalent patients receiving hemodialysis
- ✓ Performance-based frailty was defined as 3 of the following: unintentional weight loss, weakness, exhaustion, low physical activity, and slow gait speed.



Variable	Univariable		Multivariable ^a	
	OR (95% CI)	P	OR (95% CI)	P
Demographic Factors				
Age				
<65 y	1.00 (reference)	—	1.00 (reference)	—
65-75 y	2.80 (1.86-4.20)	<0.001	1.90 (1.22-2.95)	0.004
>75 y	5.55 (3.78-8.16)	<0.001	4.13 (2.72-6.29)	<0.001
Female sex	1.86 (1.37-2.54)	<0.001	1.62 (1.15-2.31)	0.006
BMI				
<18.5 kg/m ²	1.00 (reference)		1.00 (reference)	
18.5-24 kg/m ²	0.40 (0.25-0.65)	<0.001	0.37 (0.22-0.65)	<0.001
24-27 kg/m ²	0.38 (0.22-0.66)	0.001	0.35 (0.19-0.66)	0.001
>27 kg/m ²	0.32 (0.17-0.59)	<0.001	0.37 (0.19-0.74)	0.005
Socioeconomic Factors				
Education >6 y	0.52 (0.38-0.72)	<0.001		
Employed	0.24 (0.16-0.37)	<0.001		
ADL disability	6.97 (4.96-9.81)	<0.001		
Comorbidities				
Diabetes	1.75 (1.29-2.40)	<0.001	1.65 (1.15-2.37)	0.01
CAD	1.42 (1.02-1.97)	0.04		
PAD	2.03 (1.34-3.07)	0.001		
CVA	2.33 (1.38-3.92)	<0.001	2.09 (1.16-3.76)	0.02
Vascular diseases	1.79 (1.31-2.45)	<0.001		
Comorbidity index >4	1.11 (1.00-1.24)	0.05		
Dialysis				
AVG	1.88 (1.28-2.76)	0.001		
Albumin, per 1-g/dL greater	0.21 (0.13-0.34)	<0.001	0.38 (0.22-0.66)	0.001
Hemoglobin, per 1-g/dL greater	0.81 (0.72-0.91)	<0.001		

Risk factors for frailty in hemodialysis patients

A systematic review and meta-analysis

Risk Factors	No. of Studies	No. of Participants	OR/SMD	95% CI	I ² (%)	p-Value	Egger's Test p
Demographic characteristics							
→ Age (years)	6	1787	0.43 *	0.24–0.61	72	0.003	0.018
Sex (female)	7	2604	1.89	1.33 –2.67	71	0.002	0.395
Smoking, yes	3	721	1.39	0.58–3.32	80	0.005	0.186
Comorbidities							
Diabetes mellitus, yes	7	2604	2.42	1.68–3.49	73	0.001	0.108
Hypertension, yes	3	721	2.16	0.46–10.04	82	0.003	0.472
CAD, yes	3	1249	0.96	0.63–1.46	57	0.098	0.668
PVD, yes	5	1600	1.87	0.81–4.29	68	<0.001	0.240
HF, yes	4	1483	1.35	0.92–2.00	57	0.070	0.588
CVA or TIA, yes	4	1454	1.96	0.93–4.17	73	0.011	0.161
COPD, yes	3	633	1.43	0.98–2.09	0	0.835	0.532
Cancer, yes	2	516	1.35	0.48–3.84	68	0.077	NA

Note. * SMD = standardized mean difference; OR = odds ratio; CI = confidence interval; CAD = coronary artery disease; PVD = peripheral vascular disease; HF = heart failure; CVA = cerebral vascular disease; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease.


Sex-specific associations in frailty

Clinical studies in the elderly

	Finding	Reference
Pre-frailty Prevalence	Women: 39.0% (95% CI, 38.1-39.9%) Men: 37.3% (95% CI, 36.6-38.0%; $\chi^2 = 8,629$, $df = 1$, $P = 0.003$)	Systematic Review (Collard et al. 2012)
	Women: 15% (95% CI, 14-17%; $n = 143$, $I^2 = 99\%$; $P < 0.005$) Men: 11% (95% CI, 10-12%; $n = 145$, $I^2 = 97\%$; $P < 0.005$)	Meta-analysis (O’Caoimh et al. 2020)
Frailty Prevalence	Women: 9.6% (95% CI, 9.2-10%) Men: 5.2% (95% CI, 4.9-5.5%; $P < 0.001$)	Systematic Review (Collard et al. 2012)
	Women: 49% (95% CI, 14-17%; $P < 0.005$) Men: 45% (95% CI, 44-47%; $n = 119$, $I^2 = 97\%$; $P < 0.005$)	Meta-analysis (O’Caoimh et al. 2020)

Average frailty scores at each age, stratified according to sex

- Design: Secondary analysis of the Survey of Health, Ageing, and Retirement in Europe (SHARE).
- Participants: Community-dwelling adults (N = 27,527; mean age 65.3 ± 10.5 , 55% female).




Women: black circles and solid lines
Men: gray boxes and dashed lines

The “sex-frailty paradox” in the elderly

The Mexican Health and Aging Study (MHAS)

Frailty index by age and gender



Mortality hazard ratios


	All (n = 4082)	Men (n = 1932)	Women (n = 2150)
Frailty index			
.00-.07	1	1	1
.07-.14	0.93 (0.58-1.50)	0.99 (0.56-1.76)	0.83 (0.35-1.95)
.14-.21	1.56 (1.00-2.44)	1.30 (0.73-2.32)	1.84 (0.85-3.96)
.21-.35	2.20 (1.42-3.41)	2.69 (1.59-4.57)	1.73 (0.80-3.77)
.35-.65	6.45 (4.10-10.14)	5.96 (3.32-10.72)	6.63 (3.07-14.35)
Age (years)	1.05 (1.04-1.07)	1.05 (1.02-1.07)	1.06 (1.04-1.09)
Gender			
Men	1		
Women	0.66 (0.52-0.84)		




The “sex-frailty paradox” in the elderly

The Survey of Health, Ageing and Retirement in Europe (SHARE)

Women



Men



FI-associated mortality

Age Group	FI-age-adj. OR (95% CI, P)	
	Female	Male
All	100.5 (46.3–218.2) P<0.001	221.1 (106.7–458.4) P<0.001
50s	302.6 (14.2–6446.7.2) P<0.001	565.6 (74.1–4315.2) P<0.001
60s	140.9 (19.1–1038.6) P<0.001	463.7 (89.7–2396.5) P<0.001
70s	55.5 (14.6–210.9) P<0.001	267.6 (85.1–841.5) P<0.001
80s	137.0 (34.2–548.3) P<0.001	84.7 (20.1–357.1) P<0.001
90+	71.0 (7.7–650.5) P<0.001	24.7 (0.8–733.0) P=0.064

The “sex-frailty paradox”

- This phenomenon—where women exhibit a higher prevalence and greater severity of frailty, yet men experience higher mortality—is known as the sex-frailty paradox.
- This is consistent with the long-recognized observation that women have longer lifespan than men despite having higher chronic disease burden and disability.

The “sex-frailty paradox”?

In the kidney transplant candidates

Background & Methods

Understanding sex-based differences in frailty perception and its impact on outcomes is essential to prevent disparities in transplant assessments.



A prospective longitudinal cohort of 767 KT candidates in Canada

- ✓ Men: 65%
- ✓ White race 82%
- ✓ Mean age: 54 ± 14 y/o
- ✓ **75% on RRT**



Frailty assessments

- ✓ Frailty Phenotype
- ✓ Frailty Index
- ✓ Clinical Frailty Scale

Results

- ✓ The prevalence of frailty for women was not significantly higher by the FP (16% vs 13%, $p=0.15$) or the FI (48% vs 46%, $p=0.38$), but was **by the CFS (15% vs 12%, $p=0.04$)**.
- ✓ **Frailty by the CFS was significantly associated with death/withdrawal from the waitlist for men (HR 2.59, 95% CI 1.16–6.79) but not women (HR 1.41, 95% CI 0.48–4.18).**


Frailty among chronic kidney disease patients on the kidney transplant waiting list: the sex–frailty paradox

Frailty prevalence in CKD patients who are kidney transplant (KT) candidates is high, and its presence is associated with a higher rate of complications and death after transplant

Aim and methods



Barcelona, Spain



Prospective longitudinal study of **455 KT** candidates evaluated for frailty


✓ **80.9% on RRT**



Physical frailty phenotype:

- Pre-frailty = 2 criteria
- Frailty \geq 3 criteria

Results



	Pre-frail	Frail
Total	20.0%	10.3%
M : F	Male 22.5% Female 47.2%	
Characteristics:	<ul style="list-style-type: none"> • Poor family/social support • Comorbidities • Disabilities 	

Conclusion: Frailty is twice as frequent in women with advanced CKD than in men. Criteria distribution and phenotype seem also to differ among sexes.

The “sex-frailty paradox”?

In the kidney transplant candidates

Factor associated with frailty in men

	OR (95% CI)	P-value
Deficient family support	3.35 (1.37–8.23)	0.008
Instrumental activities disability	5.32 (1.86–15.15)	0.002
Haemodialysis as RRT (yes)	2.51 (1.13–5.57)	0.024
Cerebral vasculopathy	3.28 (1.01–10.62)	0.047
Heart failure	3.35 (0.95–11.92)	0.061
Peripheral vasculopathy	1.72 (0.58–5.02)	0.324
Basic activities disability	1.35 (0.38–4.77)	0.641

Factor associated with frailty in women

	OR (95% CI)	P-value
Medical treatment adherence (no)	2.75 (1.1–7.47)	0.046
Basic activities disability	8.80 (1.00–77.21)	0.050
Haemodialysis as RRT (yes)	2.22 (0.91–5.42)	0.079
Instrumental activities disability	1.91 (0.82–4.46)	0.132
Lean mass (kg/m ²)	0.86 (0.7–1.06)	0.166

The “sex-frailty paradox”?

In the hemodialysis patients

Study Design



A prospective cohort of 206 patients requiring maintenance hemodialysis in a single center

- ✓ Women: 49.5%
- ✓ Mean age: 66.9 ± 12.5 y/o
- ✓ Dialysis vintage: 7.8 (3.3–12.5) years
- ✓ Diabetes: 54.4%
- ✓ CVD: 27.7%

follow-up period
of 3.2 (1.3) yrs

Primary outcome

- ✓ All-cause mortality



Frailty assessments

- ✓ Fried Frailty Phenotype
- ✓ Clinical Frailty Scale


Baseline characteristics

Variables	Women (n=102)	Men (n=104)	<i>P</i>
Age (yr)	68.8 ± 11.2	65.1 ± 13.5	0.034
Smoking history, n (%)	4 (3.9%)	35 (33.7%)	<0.001
Dialysis vintage (yr)	7.1 (3.1–12.0)	8.1 (3.7–13.0)	0.263
nPCR (g/kg/day)	1.10 ± 0.25	1.08 ± 0.23	0.524
Body mass index (kg/m ²)	23.2 ± 3.7	23.7 ± 3.9	0.368
Diabetes mellitus, n (%)	54 (52.9%)	58 (55.8%)	0.684
Hypertension, n (%)	95 (93.1%)	91 (87.5%)	0.172
CVD, n (%)	19 (18.6%)	38 (36.5%)	0.004
Stroke, n (%)	4 (3.9%)	4 (3.8%)	0.978

Baseline characteristics

Variables	Women (n=102)	Men (n=104)	<i>P</i>
Creatinine (mg/dL)	8.4 ± 1.6	10.1 ± 2.1	<0.001
Albumin (g/dL)	3.7 ± 0.3	3.9 ± 0.3	<0.001
Fasting glucose (mg/dL)	145 (114–191)	140 (116–198)	0.916
Total cholesterol (mg/dL)	169 (142–196)	137 (113–165)	<0.001
Triglycerides (mg/dL)	144 (94–197)	133 (96–197)	0.311
LDL-C (mg/dL)	85 (68–103)	72 (55–97)	0.004
Hemoglobin (g/dL)	10.4 (9.5–11.0)	10.4 (9.5–11.1)	0.704
Calcium (mg/dL)	9.4 (8.9–10.1)	9.4 (8.8–10.0)	0.483
Phosphate (mg/dL)	4.2 (3.5–5.3)	4.5 (3.7–5.3)	0.288

Prevalence and severity of frailty



	Women (n=102)	Men (n=104)	P
Clinical Frailty Scale	4.5 (3.0–6.0)	3.0 (3.0–5.0)	0.003
Fried frailty phenotype	1.0 (0.0–3.0)	1.0 (0.0–2.0)	0.035


Association of frailty with mortality according to sex

	Model 1		Model 2	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Women				
Frailty accoridng to CFS	1.72 (0.69–4.30)	0.245	0.89 (0.31–2.55)	0.833
Frailty according to Fried phenotype	4.61 (1.05–10.37)	<0.001	2.40 (0.90–6.36)	0.079
Men				
Frailty accoridng to CFS	2.90 (1.27–6.59)	0.011	2.30 (1.01–5.27)	0.048
Frailty according to Fried phenotype	7.93 (3.64–17.29)	<0.001	6.10 (2.60–14.28)	<0.001


Model 1 is adjusted for age.

Model 2 is adjusted for age, diabetes, cardiovascular disease, and serum albumin.

Contributory domains and factors for frailty and sex-specific associations




Contributory domains and factors for frailty and sex-specific associations




Comorbidities in hospitalized ESRD patients in the prior year

	Male patients			Female patients		
	2020	2021	2022	2020	2021	2022
Cardiovascular disease	19,104(80.0%)	18,814(78.6%)	18,731(76.4%)	▶ 16,625(77.3%)	16,033(75.7%)	15,566(73.7%)
Arrhythmia	6,573(27.5%)	6,095(25.5%)	5,596(22.8%)	◀ 6,188(28.8%)	5,651(26.7%)	5,053(23.9%)
Stroke	7,351(30.8%)	6,887(28.8%)	6,444(26.3%)	▶ 6,327(29.4%)	5,826(27.5%)	5,176(24.5%)
Diabetes	11,624(48.7%)	11,452(47.9%)	11,413(46.6%)	▶ 9,552(44.4%)	9,365(44.2%)	8,921(42.3%)
COPD	5,284(22.1%)	4,791(20.0%)	4,359(17.8%)	▶ 4,043(18.8%)	3,585(16.9%)	3,203(15.2%)
Peptic ulcer disease	9,729(40.7%)	9,038(37.8%)	8,306(33.9%)	◀ 9,328(43.0%)	8,544(40.3%)	7,728(36.6%)
Malignancy	5,550(23.2%)	5,470(22.9%)	5,104(20.8%)	5,194(24.2%)	4,997(23.6%)	4,646(22.0%)
Hypertension	22,733(95.2%)	22,734(95.0%)	23,131(94.3%)	20,180(93.9%)	19,877(93.8%)	19,662(93.2%)
Dyslipidemia	9,040(37.9%)	8,888(37.1%)	9,043(36.9%)	◀ 8,878(41.3%)	8,562(40.4%)	8,480(40.2%)
Polycystic kidney disease	838(3.5%)	857(3.6%)	855(3.5%)	▶ 521(2.4%)	511(2.4%)	530(2.5%)
Peripheral vascular disease	2,138(9.0%)	1,952(8.2%)	1,774(7.2%)	1,953(9.1%)	1,766(8.3%)	1,591(7.5%)


Contributory domains and factors for frailty and sex-specific associations



Sex hormones and ACE-2 receptor




COVID-19 mortality outcomes among Medicare patients receiving long-term dialysis



Men versus women: adjusted HR (HR, 1.20; 95 %CI, 1.16-1.24)

Immune-related genes implicated in the sex-based differences in the immune response




X chromosome: genes for Toll-like receptors, cytokine receptors, and other genes important for T- and B-cell function


Y chromosome: genes for certain inflammatory pathways

A comparative analysis of nutritional parameters as predictors of outcome in male and female ESKD patients


- 206 ESKD patients (126 males) with a mean age 52+/-1 years




Contributory domains and factors for frailty and sex-specific associations



Sex differences in neural stress responses and correlation with subjective stress and stress regulation




Sex differences in neural stress responses and correlation with subjective stress and stress regulation



These sex-specific differences in stress perception may partly explain variations in women's health-related behaviors, including illness perception, self-rated health, and healthcare utilization.

Uremic symptom burden and clinical condition in women and men of ≥ 65 years of age with advanced CKD

- The European QUALity study on treatment in advanced chronic kidney disease (EQUAL)
- six European countries of ≥ 65 years of age years whose eGFR $\leq 20 \text{ mL/min/1.73m}^2$



Conclusions

- Being a woman is a risk factor for frailty among dialysis patients, whereas men with frailty exhibited higher mortality.
- The so-called “sex–frailty paradox” exists not only in the elderly but also among patients undergoing dialysis.
- This paradox highlights the importance of addressing not only frailty itself but also its underlying determinants.
- A substantial knowledge gap remains in this area, underscoring the need for further clinical research.